Hematologic and molecular responses to ropeginterferon alfa‐2b therapy of polycythemia vera: 48‐week results from a prospective study

Hematologic and molecular responses to ropeginterferon alfa‐2b therapy of polycythemia vera: 48‐week results from a prospective study

Abstract To prevent thrombosis in patients with polycythemia vera (PV), achieving a complete hematologic response (CHR) is highly recommended in practice. In addition, a reduced JAK2 V617F mutation burden is expected to have a disease‐modifying effect, and its molecular response (MR) is currently of...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Seug Yun Yoon, Sung‐Soo Yoon, Deok‐Hwan Yang, Gyeong‐Won Lee, Sang Kyun Sohn, Ho‐Jin Shin, Sung Hwa Bae, Chul Won Choi, Eun‐Ji Choi, June‐Won Cheong, Soo‐Mee Bang, Joon Seong Park, Suk Joong Oh, Yong Park, Young Hoon Park, Sung‐Eun Lee
Médium: Artigo
Jazyk:angličtina
Vydáno: 2025
On-line přístup:https://doi.org/10.1002/ijc.35411
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Internet

https://doi.org/10.1002/ijc.35411

Podobné jednotky